SANTA CLARA, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2020. Recent Highlights Recognized revenue of $10.3 million […]
Other News
Neovasc Announces Closing of US$12.6 Million Registered Direct Offering Priced At-The-Market
Vancouver, Canada, Aug. 12, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under the Nasdaq rules of an aggregate of 4,532,772 common shares at a […]
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
TARRYTOWN, N.Y., Aug. 12, 2020 /PRNewswire/ — Homozygous familial hypercholesterolemia affects approximately 1,300 patients in the U.S., the vast majority of whom are unable to reach target LDL-C levels with currently available therapies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a […]
Medicure Reports Financial Results for Quarter Ended June 30, 2020
WINNIPEG, MB, Aug. 11, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2020. Quarter Ended June 30, 2020 Highlights: Net income for the quarter ended June 30, 2020 was $19,000 compared to net loss of $957,000 for the quarter ended June 30, […]
Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2020 and provided a clinical and corporate update. “With the benefit of having completed our first Phase 3 clinical trial and […]
Itamar Medical Reports Second Quarter 2020 Financial Results
– Second Quarter Revenues Increase 21% to $8.9 Million – – U.S. WatchPATTM Revenues Increase 31% to $6.6 Million – – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT – CAESAREA, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a […]
Myocardial Solutions Announces Strategic Partnership with United Imaging, Bringing Rapid Cardiac MR Imaging to Unmet Cancer Care and Cardiology Markets
MORRISVILLE, N.C., Aug. 11, 2020 /PRNewswire/ — Myocardial Solutions, Inc. (“MSI”) and United Imaging, Inc. (“United Imaging”) have formed a strategic partnership to open new cancer care and cardiology markets for rapid cardiac magnetic resonance (MR) imaging. The partnership will focus on providing cancer centers and hospitals with critical MyoStrain®-enabled solutions for the […]
JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials
JAN101 formulation ready for Phase 2b peripheral artery disease trials and for potential treatment of COVID-19 vascular inflammation LAS VEGAS, Aug. 11, 2020 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, together with its manufacturing partner, […]
PIH Health Good Samaritan Hospital Offers an Alternative to Long-Term Warfarin Medication for Atrial Fibrillation with Next-Generation Watchman FLX™ Implant
LOS ANGELES, Aug. 10, 2020 /PRNewswire/ — PIH Health Good Samaritan Hospital is one of the first hospitals in Los Angeles to offer the next-generation Watchman FLX™ Left Atrial Appendage Closure (LAAC) implant to patients with non-valvular atrial fibrillation (AF). The implant is an alternative to long-term warfarin medication. Up to 6 million Americans are […]
MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China
Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) and LianBio announced […]



